Citius Pharma subsidiary Citius Oncology says new LYMPHIR institutional accounts jump 78% Q/Q
Reuters2026/08/05 13:27- Citius Pharma’s majority-owned unit Citius Oncology reported faster early uptake for LYMPHIR in cutaneous T-cell lymphoma.
- New institutional accounts ordering LYMPHIR rose 78% quarter over quarter in the June 30, 2026 quarter; total institutional vial orders increased 31%.
- LYMPHIR reached 42 institutions; Citius Oncology expects more than 20 additional institutions in the current quarter.
- Near-universal payer coverage cited; initial CTCL market opportunity for LYMPHIR pegged at more than USD 400 million.
- Revenue recognition tied to wholesale orders placed and filled; wholesalers have started reordering as demand increases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
